

References

Scientific publications

1. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720.
2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26;360(13):1310-9.
3. Ablin RJ The Great Prostate Mistake. NYT. March 9, 2010.
4. Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM. Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med. 2013 May 27; 173(10): 866–873.
5. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89
6. Siegel DA, O'Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480.
7. Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.fr/today>.
8. Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 1997;158:2162-7.
9. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969-74.
10. Bill-Axelsson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Andréén O, Steineck G, Adami HO, Johansson JE. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018 Dec 13;379(24):2319-2329.
11. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 Jul 13;377(2):132-142.
12. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Oct 13;375(15):1415-1424.
13. Zelefsky MJ, Gomez DR, Polkinghorn WR, Pei X, Kollmeier M. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes. Int J Radiat Oncol Biol Phys 2013; 86: 529-33.
14. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-73.
15. Bolla M, de Reijke TM, Tienhoven GV, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
16. Lam TBL et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study. Eur Urol. 2019 Dec;76(6):790-813.

17. Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ; PRIAS study group. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. *Eur Urol.* 2016 Dec;70(6):954-960.
18. Van Hemelrijck M et al. Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. *Eur Urol.* 2019 Mar;75(3):523-531.
19. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat Med.* 2009 May;15(5):559-65.
20. Haffner MC, Mosbrugger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Tracking the clonal origin of lethal prostate cancer. *J Clin Invest.* 2013 Nov;123(11):4918-22.
21. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L; International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. *J Urol.* 2007 Dec;178(6):2260-7.
22. Mozer P, Rouprêt M, Le Cossec C, Granger B, Comperat E, de Gorski A, Cussenot O, Renard-Penna R. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. *BJU Int.* 2015 Jan;115(1):50-7.
23. Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu JA, Lotan Y, Francis F, Pedrosa I, G Roehrborn C, Costa DN. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. *Urol Oncol.* 2019 Jan;37(1):57-62
24. Garcia-Barreras S, Sanchez-Salas R, Sivaraman A, Barret E, Secin F, Nunes-Silva I, Linares-Espinós E, Rozet F, Galiano M, Cathelineau X. Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low and Intermediate Risk Prostate Cancer: Oncologic and Functional Outcomes. *J Urol.* 2018 Jan;199(1):140-146.
25. Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclaus F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghrou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol.* 2017 Feb;18(2):181-191.
26. High Intensity Focalized Ultrasound for the treatment of localized prostate cancer. Haute Autorité de Santé / Department of Medical and Surgical Procedures Assessment / December 2010
27. Azzouzi AR, Lebdai S, Benzaghrou F, Stief C. Vascular-targeted photodynamic therapy with **TOOKAD® Soluble** in localized prostate cancer: standardization of the procedure. *World J Urol.* 2015 Jul;33(7):937-44.
28. Tookad Early Prostate Cancer Clinical Team Received the Inaugural Tayyaba Hasan IMPACT Award at the 17th World Congress of the International Photodynamic Association. <https://ph.news.yahoo.com/tookad-early-prostate-cancer-clinical-171959711.html>
29. Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, Villers A, Coleman J, Allen C, Scherz A, Emberton M. **TOOKAD® Soluble** focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. *World J Urol.* 2015 Jul;33(7):945-53.
30. Rodriguez-Rivera JA, Rodriguez-Lay R, Zegarra-Montes L, Benzaghrou F, Gaillac B, Azzouzi AR, Reis LO, Palma P. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study. *Actas Urol Esp.* 2018 Dec;42(10):632-638.

31. Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, Moore CM, Nigam R, Ogden C, Persad R, Shah K, van der Meulen J, Viridi J, Winkler M, Emberton M, Ahmed HU. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. *Eur Urol.* 2018 Oct;74(4):422-429.
32. Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, Hosking-Jervis F, Thomas B, Dudderidge T, Hindley RG, McCracken S, Greene D, Nigam R, Valerio M, Minhas S, Winkler M, Arya M, Ahmed HU. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. *Eur Urol.* 2019 Jul;76(1):98-105
33. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. *BJU Int.* 2012 Jun;109(11):1648-54.
34. Murray KS, Ehdaie B, Musser J, Mashni J, Srimathveeravalli G, Durack JC, Solomon SB, Coleman JA. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer. *J Urol.* 2016 Sep;196(3):883-90.
35. Colletini F, Enders J, Stephan C, Fischer T, Baur ADJ, Penzkofer T, Busch J, Hamm B, Gebauer B. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. *Radiology.* 2019 Jul;292(1):250-257.
36. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. TAX 327 Investigators. *N Engl J Med.* 2004 Oct 7;351(15):1502-12.
37. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet.* 2010 Oct 2;376(9747):1147-54
38. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *N Engl J Med.* 2015 Aug 20;373(8):737-46.
39. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med.* 2014 Jul 31;371(5):424-33.
40. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med.* 2011 May 26;364(21):1995-2005.
41. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winkler M, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med.* 2013 Jan 10;368(2):138-48.
42. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. AFFIRM Investigators. *N Engl J Med.* 2012 Sep 27;367(13):1187-97.

43. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med.* 2020 Dec 10;383(24):2345-2357.
44. Lebastchi AH, George AK, Polascik TJ, Coleman J, de la Rosette J, Turkbey B, Wood BJ, Gorin MA, Sidana A, Ghai S, Tay KJ, Ward JF, Sanchez-Salas R, Muller BG, Malavaud B, Mozer P, Crouzet S, Choyke PL, Ukimura O, Rastinehad AR, Pinto PA. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. *Eur Urol.* 2020 Sep;78(3):371-378.
45. van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, Lam TB, Mason MD, Rouvière O, De Santis M, Willemse PM, van Poppel H, Mottet N. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. *Eur Urol.* 2018 Jul;74(1):84-91.
46. Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. *J Urol.* 2020 Jan;203(1):115-119.
47. Valerio M, Emberton M, Ahmed HU. Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. *Eur Urol* 2018;74:84-91. *Eur Urol.* 2019 Feb;75(2):e21-e22.
48. Lebdai S, Gigoux M, Alvim R, Somma A, Nagar K, Azzouzi AR, Cussenot O, Merghoub T, Wolchok JD, Scherz A, Kim K, Coleman J. Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. *Oncoimmunology.* 2019 Mar 28;8(6):e1581528.

Tables

Table 1 : The tumour (T) parameter of the TNM classification of prostate cancer

Table 2 : Acceptable range of PSA related to age

Table 3 : Probability of prostate cancer according to PSA blood test (source : EAU guidelines 2020)

Table 4 : Prostate cancer detection rates by mpMRI based on tumour volume and ISUP classification (source : EAU guidelines 2020)

Table 5 : ISUP prostate cancer grade groups in correlation with the Gleason score grading

Table 6 : No Difference in oncological or incontinence/erectile dysfunction results between open/laparoscopic/robotic approach (source : EAU guidelines 2020)

Table 7 : Recommendations of the EAU regarding the indication of radical prostatectomy in the different risk groups (source : EAU guidelines 2020)

Table 8 : Strong scientific evidence of the absence of efficacy of radical treatments compared to simple surveillance on mortality (source : EAU guidelines 2020)

Table 9 : Mortality rate after radical prostatectomy in the 3 most reliable studies in the field (source : EAU guidelines 2020)

Table 10 : Recommendations of the EAU regarding the indication of EBRT or HRT in the different risk groups (source : EAU guidelines 2020)

Table 11 : Efficacy and toxicity results of the main EBRT RCTs

Table 12 : Recommendations of the EAU regarding the indication of brachytherapy in the different risk groups (source : EAU guidelines 2020)

Table 13 : Results of LDR brachytherapy (source : EAU guidelines 2020)

Table 14 : Results of combined radiation therapies EBRT + HDR brachytherapy

Table 15 : Differences between the active surveillance and watchful waiting (source EAU 2020)

Table 19 : Active surveillance criteria according to different institutions or learning societies
Table 17 : Recommendations of the EAU regarding the indications of AS in the LR and IR risk groups (source : EAU guidelines 2020)
Table 18 : Cancer Specific Survival (CSS) and Overall Survival (OS) results in active surveillance at 10 years (source EAU 2020)
Table 19 : d'Amico classification updated

Pictures

Picture 1 : Pathological constitution of the normal prostatic gland
Picture 2 : The chesnut is a very common comparison to the prostatic gland size and shape
Picture 3 : With age an increasing prostate size is the rule not the exception
Picture 4 : Urinary sphincter immediately underneath the prostate (by B. Batard)
Picture 5 : Neuro-vascular bundles (NVB) running posteriorly alongside the prostate. In 75% the NVBs are bilaterally well-delimited and dissectable, and in 25% the NVBs are spread and impossible to preserve. Before an ablation of the prostate, the NVBs anatomy is not predictable (by B. Batard)
Picture 6 : Zonal anatomy according to Mc Neal description
Picture 7 : Transversal cross sectional view of the different zones of the prostate
Picture 8 : 3D sagittal cross sectional view of the different zones of the prostate
Picture 9 : Molecular composition of testosterone
Picture 10 : 3D molecular structure of the androgen-receptor
Picture 11 : Different definitions of prostate cancer according to Pr O. Cussenot
Picture 12 : A thoughtful sentence
Picture 13 : Worldwide incidence and mortality rates (source WHO)
Picture 14 : The important role of age in the mortality rate due to prostate cancer
Picture 15 : Cussenot-Tassin hereditary transmission model (by courtesy of Pr O. Cussenot)
Picture 16 : a) Digital rectal examination on a sagittal anatomical view (by B. Batard)
b) Presence of the tumour into the prostate according to the T stage
Picture 17 : 3D molecular structure of the Prostatic Specific Antigen (PSA)
Picture 18 : Transrectal ultrasound (TRUS) with the immediate proximity of the prostate to the US probe (by B. Batard)
Picture 19 : Axial T2W sequence (by courtesy of Dr F. Tobolski - Integratome)
Picture 20 : DWI sequence (by courtesy of Dr F. Tobolski - Integratome)
Picture 21 : DCE sequence (by courtesy of Dr F. Tobolski - Integratome)
Picture 22 : PIRADS 1 to 5 illustration (by courtesy of Dr P. Steiger - Klinik Beau-Site)
Picture 23 : A superconducting magnet with a spatial resolution of about 0.1 mm compared to 1 mm today
Picture 24 : A first milestone in the prostate imaging approach (Liddell HT et al. J. Urol. 1986)
Picture 25 : Application of an enema few hours before the biopsy procedure (by B. Batard)
Picture 26 : Antibioprophylaxia to reduce the risk of acute prostatitis - To take orally 1-2 hours or intravenously just before the biopsy
Picture 27 : a) Transrectal xylocaine injection into the prostate-seminal vesicle angle b) Transperineal xylocaine injection under the perineal skin (by B. Batard)
Picture 28 : Lateral decubitus position - only for transrectal biopsies
Picture 29 : 12 spots scheme applied without distinction amongst patients
Picture 30 : EAU first biopsy set scheme
Picture 31 : 3D prostate with unreached anterior lesion (in brown)
Picture 32 : High resolution targeted biopsy procedure based on a MRI/US fusion system
Picture 33 : Biopsy gun with a Tru-cut needle
Picture 34 : Sagittal view of transperineal targeted biopsies (by B. Batard)
Picture 35 : Ginsburg protocol scheme (source : European Urology)
Picture 36 : The d'Amico classification with the risk of recurrence

Picture 37 : The first radical prostatectomy at the John Hopkins Hospital (Baltimore, US) and the concomitant publication of the first serie of 4 cases

Picture 38 bis : Surgical site of a perineal radical prostatectomy

Picture 39 : Barré-Chauveau technique - Santorini plexus + urethral section

Picture 40 : Laparoscopic installation with abdominal positioning of trocars

Picture 41 : Ablation of the prostate with immediate proximity of the urinary sphincter explaining the incontinence rate (by B. Batard)

Picture 42 : The Theratron junior a Cobalt-60 radiation therapy equipment in use in the 50's

Picture 43 : Three-dimensional conformal radiation therapy (3D-CRT) radiation fields

Picture 44 : Intensity modulated radiation therapy (IMRT) radiation fields

Picture 45 : Stereotaxic body radiation therapy (SBRT) radiation fields

Picture 46 : In 1911 the Pasteau-Degrais technique in Paris

Picture 47 : Drawing of the Barringer interstitial technique in the MSKCC (1924)

Picture 48 : Needle placement for permanent seeds during a LDR brachytherapy procedure (by B. Batard)

49 : Active surveillance protocols are based on the ancient diagnostic triad

50 : Reasons and proportions of discontinuation of active surveillance (source : Movember GAP3 Consortium)

Picture 51 : Multifocal prostate cancer lesions on mpMRI (by courtesy of Dr F. Tobolski - Integratome)

Picture 52 : Multifocal prostate cancer with a more important lesion of the right lobe

Picture 53 : The index lesion is the most important lesion and leads the prognosis of the disease

Picture 54 : Metastatic spread of the disease starting from the index lesion (in black) while the other lesion plays (yellow and green) a secondary role. The mechanism of metastasis spread is either direct from the prostate or indirect by a first metastase which will latter spread. (source : Liu W. Nat. Med. 2009)

Picture 55 : Percutaneous CT scan-guided ablation of a kidney tumour by cryotherapy

Picture 56 : Prostate biopsy mapping record

Picture 57 : MRI at day-7 of an hemi-ablation of the right lobe

Picture 58 : Sagittal view of the installation during the illumination phase

Picture 59 : Lancet Oncology publication February 2017 - Level 1 scientific evidence

Picture 60 : From the laser activation of Tookad® to the cells death

Picture 61 : Compilation of titles of Prostate Photodynamic Therapy-related scientific articles

Picture 62 : The accuracy of the necrosis by the Prostate Photodynamic Therapy Technique

Picture 63 : The protective role of the capsule on the integrity of the erectile nerves

Picture 64 : The HIFU device contains 2 transducers : low-intensity for the imaging and high-energy for the treatment

Picture 65 : The Joule-Thompson effect

Picture 66 : The production of iceball at the tip of cryoprobes

Picture 67 : Biological effect of cryotherapy on cells and targeted tissue

Picture 68 : Sagittal view of a cryotherapy procedure with intraprostatic iceballs

Picture 69 : Disruption of the cell membrane by electroporation (adapted from Tsong TY. Biophys J 1991)

Picture 70 : Sagittal view of the IRE installation and needle-like electrodes placement (by B. Batard)

Picture 71 : Placement of the needle-like electrodes according to the triangulation method

Picture 72 : Milestones of systemic treatments in advanced prostate cancer

Picture 73 : Publication princeps of C. Huggins and C.V. Hodges in Cancer Research in 1941

Picture 74 : The hypothalamus pituitary gland axis

Picture 75 : Port a catheter on the right breast

Picture 76 : Molecular structure of abiraterone acetate

Picture 77 : Mechanism of action of enzalutamide in the androgen receptor signaling pathway (source : Rodriguez-vida A. et al. Drug Design, Development and Therapy 2015)

Picture 78 : PARP inhibitor blocking the MMR system pathway leading to tumoral cell death (source : Cancer UK)

Picture 79 : Inactivation of a T-cell by PD-L1 and PD-L2 ligand binding to PD-1 receptor (source : www.keytrudahcp.com)

Picture 80 : Competitive binding of pembrolizumab on the PD-1 receptor blocking the interaction with PD-L1 and PD-L2 and restoring the T-cell immune response (source www.keytrudahcp.com)

Picture 81 : Mechanism of action of Sipuleucel-T (source : Handy CE and Antonarakis ES. Future Oncol. 2018)

Picture 82 : Radical prostatectomy failure expressed by PSA reascencion (source : Milonas D. et al. Front. Oncol. 2019)

Picture 83 : Different failure definitions give different results (source : Miyake M. et al. Prostate International. 2019)

Picture 84 : Connecting experts knowledge to reach a consensus

Picture 85 : 12-millimeter ISUP 2 prostate cancer lesion perfectly suitable for focal therapy

Picture 86 : The ProtecT study published in one of the most famous medical review in 2016

Picture 87 : A very delicate and accurate introduction of the needles

Picture 88 : Therapeutic scheme including focal therapies as alternative to radical treatments in selected LR and favourable IR groups

Picture 89 : FDA Oncology Center of Excellence Public Workshop report (2020)

Picture 90 : A patient-doctor relationship based on full understanding and confidence

Videos

Video 1 : What is the prostate ? (Prostate - Anatomy of the prostate)

Video 2 : Prostate cancer is a slow growing disease (Everything you need to know about prostate cancer)

Video 3 : Genetic impact on prostate cancer (Prostate Cancer - Epidemiology)

Video 4 : Undeniable scientific evidence (Validated treatments - Surgery)

Video 5 : The brachytherapy technique (Validated treatments - Brachytherapy)

Video 6 : The proof of concept of focal therapy based on the index lesion (Optional treatments – Focal therapy - Proof of Concept)

Video 7 : MRI/US fusion : the missing link (Optional treatments - Focal therapy - The MRI-based targeting concept)

Video 8 : An efficient devascularization of a tumour after activation of Tookad[®] by the laser light (Optional treatments - Phototherapy)

Video 9 : The deep science behind the prostate photodynamic therapy (Optional treatments - Phototherapy - Scientific basis)

Video 10 : Animation of the Prostate Photodynamic Therapy Technique (Optional treatments - Phototherapy - Technique)

Video 11 : The Prostate Photodynamic Therapy Technique commented with Prs AR Azzouzi and J Rassweiler (Optional treatments - Phototherapy - Technique)

Video 12 : The prostate photodynamic therapy procedure (Optional treatments - Phototherapy - Technique)

Video 13 : Indications of the prostate photodynamic therapy (Optional treatments - Phototherapy – Indications/Results)

Video 14 : Results of the prostate photodynamic therapy (Optional treatments - Phototherapy – Indications/Results)

Figures

Figure 1 : Proportion of benign, ISUP 1 and ISUP ≥ 2 related to PSAD (Prostate cancer – Diag. Tools)

Figure 2 : Risk of prostatic cancer depending on the PI-RADS v2 score (source : EAU guidelines) (Prostate cancer – Diag. Tools – mpMRI)